[1] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

[2] Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis

[3] Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis

[4] Vedolizumab for induction and maintenance of remission in ulcerative colitis

[5] Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

[6] Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

[7] Vedolizumab as induction and maintenance therapy for ulcerative colitis

[8] Specific detection of bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction

[9] Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

[10] Deep remission in inflammatory bowel disease: looking beyond symptoms

[11] Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab

[12] Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

[13] Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

[14] Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease

[15] Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications

[16] Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea

[17] Treatment Targets in Inflammatory Bowel Disease: Current Status in Daily Practice

[18] Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis

[19] Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC

[20] Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

[21] Mucosa-associated bacterial flora of the human colon

[22] Antibacterial antibodies in rectal and colonic mucosa in ulcerative colitis

[23] Associations of sense of coherence with psychological distress and quality of life in inflammatory bowel disease

[24] Pouchitis: result of microbial imbalance?

[25] Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response

[26] Inflammatory bowel disease

[27] Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

[28] Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial

[29] Adhesive and hydrophobic properties of Escherichia coli from the rectal mucosa of patients with ulcerative colitis

[30] Potential molecular biomarkers used to predict the response to biological therapies in ulcerative colitis

[31] Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease

[32] Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

[33] Anti-Colitic Effects of Ethanol Extract of Mill. through Suppression of Pro-Inflammatory Mediators via NF-κB/STAT3 Inactivation in Dextran Sulfate Sodium-Induced Colitis Mice.

[34] Effect of Shogaol on the Expression of Intestinal Stem Cell Markers in Experimentally Induced Colitis in BALB/c Mice

[35] The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis

[36] The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis

[37] Therapeutic effect of gold nanoparticles on DSS-induced ulcerative colitis in mice with reference to interleukin-17 expression

[38] Differential Intestinal Mucosa Transcriptomic Biomarkers for Crohn’s Disease and Ulcerative Colitis

[39] Distinct patterns of naive, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn's disease.

[40] Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática

[41] Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.

[42] The combination of indirubin and isatin attenuates dextran sodium sulfate induced ulcerative colitis in mice.

[43] Protective effect of Lactobacillus fermentum CQPC04 on dextran sulfate sodium-induced colitis in mice is associated with modulation of the nuclear factor-κB signaling pathway.

[44] Endoscopy in Postoperative Patients with Crohn's Disease or Ulcerative Colitis. Does It Translate to Better Outcomes?

[45] [Method of diagnosis of the severity of the disease attack in patients with ulcerative colitis.]

[46] Costus root granules improve ulcerative colitis through regulation of TGF-β mediation of the PI3K/AKT signaling pathway.

[47] Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis

[48] Appropriate Timing of Discontinuation of Tacrolimus Therapy for Refractory Ulcerative Colitis

[49] Ambient air quality as risk factor for microscopic colitis - A geographic information system (GIS) study.

[50] Application of a DSS colitis model in toxicologically assessing norisoboldine.

[51] Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam.

[52] Analgesic effect of resveratrol on colitis-induced visceral pain via inhibition of TRAF6/NF-κB signaling pathway in the spinal cord.

[53] Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.

[54] Cyanidin-3--Glucoside and Cyanidin Protect Against Intestinal Barrier Damage and 2,4,6-Trinitrobenzenesulfonic Acid-Induced Colitis.

[55] Microscopic colitis: diagnosis and management.

[56] Healing effects of Cornus mas L. in experimentally induced ulcerative colitis in rats: From ethnobotany to pharmacology.

[57] Healing effects of Cornus mas L. in experimentally induced ulcerative colitis in rats: From ethnobotany to pharmacology

[58] Modulation of gut microbiota by Ilex kudingcha improves dextran sulfate sodium-induced colitis.

[59] Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis.

[60] Decreasing Colectomy Rates in Ulcerative Colitis in the Past Decade: Improved Disease Control?

[61] Saccharomyces cerevisiaeCNCMI-3856 prevents colitis induced by AIEC bacteria in the transgenic mouse model mimicking Crohn's disease

[62] AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition

[63] Tu2024 AIEC Instigates Chronic Colitis by Altering Microbiota Composition and Its Inherent Pro-Inflammatory Potential

[64] Sa1753 Vertical Transmission of AIEC Pathobiont Increases Severity of DSS-Induced Colitis in Offspring

[65] Characteristics and outcomes of acute colitis diagnosed on cross-sectional imaging presenting via the emergency department in an Irish academic medical centre.

[66] Functional and quality of life outcomes after ileal pouch-anal anastomosis in short versus long ileal J-pouch configuration in ulcerative colitis patients: a cohort study.

[67] Filtered Kombucha tea ameliorates the leaky gut syndrome in young and old mice model of colitis.

[68] Therapeutic effect of adenosine on experimentally induced acute ulcerative colitis model in rats.

[69] Tricellulin is regulated via interleukin-13-receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis

[70] Orally administered gold nanoparticles protect against colitis by attenuating Toll-like receptor 4- and reactive oxygen/nitrogen species-mediated inflammatory responses but could induce gut dysbiosis in mice.

[71] Maternal High Fat Diet Alters Gut Microbiota of Offspring and Exacerbates DSS-Induced Colitis in Adulthood

[72] Ulcerative Colitis: A Critical Approach to the Global Research Output Employing Density-equalizing Mapping and Scientometric Methods.

[73] Effects of Aqueous and Methanolic Extracts of Stem Bark of De Wild. (Apocynaceae) on Dextran Sodium Sulfate-Induced Ulcerative Colitis in Wistar Rats.

[74] Rapid expansion of Treg cells protects from collateral colitis following a viral trigger

[75] Risk factors for ulcerative colitis-associated colorectal cancer: A retrospective cohort study.

[76] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

[77] Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1

[78] Chemotaxonomic Analysis of Bacterial Populations Colonizing the Rectal Mucosa in Patients with Ulcerative Colitis

[79] Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis

[80] Inflammatory colonic carcinogenesis: A review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis

[81] Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis

[82] Vedolizumab for induction and maintenance of remission in ulcerative colitis

[83] Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

[84] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

[85] Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis

[86] Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

[87] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

[88] Vedolizumab as induction and maintenance therapy for ulcerative colitis

[89] Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

[90] Psychological status in Iranian patients with ulcerative colitis and its relation to disease activity and quality of life

[91] Psychological status in Iranian patients with ulcerative colitis and its relation to disease activity and quality of life

[92] Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients

[93] nrf-2 expression in ulcerative colitis lesions and its correlation with antioxidant enzyme levels and tissue injury

[94] reactive oxygen species deficiency due to ncf1-mutation leads to development of adenocarcinoma and metabolomic and lipidomic remodeling in a new mouse model of dextran sulfate sodium-induced colitis

[95] pseudomembranous colitis: not always caused by clostridium difficile

[96] the crohn’s and colitis foundation of canada: a time for reflection and strategic planning for the future

[97] intestinal anti-inflammatory effects of outer membrane vesicles from escherichia coli nissle 1917 in dss-experimental colitis in mice

[98] possibility of interstitial lung disease as a phlebosclerotic colitis manifestation

[99] sucralose promotes colitis-associated colorectal cancer risk in a murine model along with changes in microbiota

[100] boehmeria nivea attenuates the development of dextran sulfate sodium-induced experimental colitis

[101] markers of hypoxia correlate with histologic and endoscopic severity of colitis in inflammatory bowel disease